Transdermal testosterone gel (Testogel 1% ) + Matched transdermal placebo gel
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Frailty
Conditions
Frailty, Sarcopenia
Trial Timeline
Oct 1, 2004 → Dec 31, 2008
NCT ID
NCT00190060About Transdermal testosterone gel (Testogel 1% ) + Matched transdermal placebo gel
Transdermal testosterone gel (Testogel 1% ) + Matched transdermal placebo gel is a approved stage product being developed by Bayer for Frailty. The current trial status is completed. This product is registered under clinical trial identifier NCT00190060. Target conditions include Frailty, Sarcopenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00190060 | Approved | Completed |
Competing Products
3 competing products in Frailty
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Longeveron Mesenchymal Stem Cells (LMSCs) | Longeveron | Phase 2 | 44 |
| Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) + Placebo + Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Longeveron | Phase 1/2 | 33 |
| Longeveron Mesenchymal Stem Cells (LMSCs) + Fluzone High Dose Vaccine | Longeveron | Phase 1/2 | 33 |